These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27247321)

  • 1. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
    Zinzani PL; Pellegrini C; Argnani L; Broccoli A
    Haematologica; 2016 Sep; 101(9):e385-6. PubMed ID: 27247321
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
    Reddy NM; Greer JP; Morgan DS; Chen H; Park SI; Richards KL
    Leukemia; 2017 Jan; 31(1):241-244. PubMed ID: 27654851
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical Efficacy Comparison of Different Second Line Salvage Chemotherapy Regimens for the Treatment of Elderly Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma].
    Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):448-51. PubMed ID: 27151008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
    Zinzani PL; Pellegrini C; Derenzini E; Argnani L; Pileri S
    Hematol Oncol; 2013 Dec; 31(4):223-4. PubMed ID: 23620452
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
    Zinzani PL; Pellegrini C; Gandolfi L; Stefoni V; Quirini F; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):462-6. PubMed ID: 21859554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
    Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
    J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
    Krawczyk K; Jurczak W; Gałązka K; Gruchała A; Skotnicki AB
    J Med Case Rep; 2014 Oct; 8():325. PubMed ID: 25277681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
    Hernandez-Ilizaliturri FJ; Deeb G; Zinzani PL; Pileri SA; Malik F; Macon WR; Goy A; Witzig TE; Czuczman MS
    Cancer; 2011 Nov; 117(22):5058-66. PubMed ID: 21495023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
    Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 15. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A; Conde E; Arnan M; Canales MA; Deben G; Sancho JM; Andreu R; Salar A; García-Sanchez P; Vázquez L; Nistal S; Requena MJ; Donato EM; González JA; León A; Ruiz C; Grande C; González-Barca E; Caballero MD;
    Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Di Raimondo C; Abdulla FR; Zain J; Querfeld C; Rosen ST
    Br J Haematol; 2019 Nov; 187(3):e79-e82. PubMed ID: 31566707
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
    Desai M; Newberry KJ; Romaguera J; Zhang L; Ou Z; Wang M
    J Hematol Oncol; 2013 Aug; 6():55. PubMed ID: 23915913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report.
    Li C; Zhang X; Zhu D; Bu X; Wang L; Zhao P
    Ann Hematol; 2023 Dec; 102(12):3625-3627. PubMed ID: 37608197
    [No Abstract]   [Full Text] [Related]  

  • 20. Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP.
    Kang HJ; Kim WS; Suh C; Park YH; Kim BS; Yuh YJ; Ryoo BY
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):299-304. PubMed ID: 17922274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.